- Advertisement -
KARACHI, Nov 13 (APP):The Center for Bioequivalence Studies and Clinical Research (CBSCR) at the Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD), University of Karachi, has recently signed a Mutual Confidentiality and Nondisclosure Agreement (NDA) with Minerva Research Solutions, Karachi.
According to a spokesperson for the International Center for Chemical and Biological Sciences (ICCBS), University of Karachi on Thursday, the primary objective of the NDA is to establish collaboration in the fields of clinical trials and bioequivalence studies.
The NDA was signed by Prof. Dr. Muhammad Raza Shah, Director, ICCBS, University of Karachi, and Dr. Ashfaq Ahmed, Director, Business Development & Operations, Minerva Research Solutions.
The signing ceremony was held at the HEJ Research Institute of Chemistry, University of Karachi.
Prof. Dr. Muhammad Raza Shah said that the CBSCR is a world-renowned research center and a component of the Dr. Panjwani Center. He noted that the CBSCR is now fully operational and has completed bioequivalence (BE) and pharmacokinetic studies in compliance with national and international guidelines.
He added that the center also houses the country’s first clinical trial facility, capable of conducting studies in accordance with international standards.
He described the signing of the NDA as “an important step in strengthening academic–industry collaboration to advance research and innovation in pharmaceutical and biomedical sciences.”
Dr. Ashfaq Ahmed said that Minerva Research Solutions hopes this partnership will foster mutual trust and facilitate meaningful scientific engagement built on transparency and respect for intellectual property.
The agreement will remain in effect for three years, with specific confidentiality obligations extending beyond the term of the contract, ensuring sustained protection of proprietary knowledge and research data.